---
author: Pooja Choubey, Ph.D.
title: Molecular Genetics & QC Regulatory Compliance Benchmark
date: 2026-03-02
role: Principal Research Scientist
---

# Molecular Genetics & QC Regulatory Compliance Benchmark

## 1. Domain Overview: GLP/GCP Regulatory Frameworks

As a Principal Research Scientist, ensuring the integrity, reproducibility, and safety of genomic data across clinical and laboratory settings is paramount. This artifact outlines the necessary quality control (QC) parameters and regulatory guardrails required for NGS, CRISPR-Cas9, and RNA-Seq workflows.

### 1.1 Core Foundations of Lab Systems Compliance

- **ALCOA+ Principles**: Ensuring all research data is Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available.
- **FDA 21 CFR Part 11**: Guidelines on electronic records and electronic signatures to ensure data authenticity, integrity, and confidentiality.
- **ISO 13485**: Quality management system requirements for the design and manufacture of medical devices, directly applicable to novel genomic diagnostics.

## 2. Genomic Quality Control Matrices

To guarantee high-fidelity data extraction without protocol deviations or technical variance (batch effects), we utilize stringent primer design and sequencing specifications.

### 2.1 Primer Design Specs (QC Table)

| Primer ID | Target Gene | Sequence (5' -> 3') | Tm (°C) | GC Content (%) | Amplicon Size (bp) | QC Status |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| **BRCA1-Ex2-F** | BRCA1 | AGATGCCTCTCAAACGG | 60.1 | 48.5 | 250 | **Validated** |
| **BRCA1-Ex2-R** | BRCA1 | CTTGCGGACTCTAGTG | 59.8 | 50.0 | 250 | **Validated** |
| **CTCF-Prom-F** | CTCF | GCGTTACGCCAAATTAG | 58.0 | 45.4 | 185 | **Under Review** |
| **CRISPR-gRNA-1** | Cas9 | AGCGTACGCGTACCG | 62.5 | 60.0 | 20 | **Validated** |

### 2.2 RNA-Seq Quality Thresholds

- **RIN (RNA Integrity Number)**: Must be $\geq 8.0$ for high-quality library preparation.
- **Total Depth**: Minimum $30 \times 10^6$ mapped reads per sample for differential expression analysis.
- **Technical Variance Mitigation**: Apply surrogate variable analysis (SVA) via Bioconductor to account for batch effects across sequencer runs.

## 3. Incident Management: Protocol Deviation Response

In the event of a sample loss incident or contamination:

1. **Immediate Halt**: Suspend all downstream pipeline processing.
2. **Quarantine**: Isolate the affected RNA/DNA libraries.
3. **Root Cause Analysis (RCA)**: Investigate automated pipetting logs, thermal cycler calibrations, and reagent expiration dates.
4. **CAPA**: Issue a Corrective and Preventive Action report detailing the remediation to prevent recurrence.

## 4. Closing Statement

*“Precision medicine requires precision execution. Our molecular pipelines must withstand regulatory scrutiny just as rigorously as they withstand scientific peer review.”* — **Pooja Choubey, Ph.D.**
